The Journal of Immunology, Vol 141, Issue 4 1131-1136, Copyright © 1988 by American Association of Immunologists

ARTICLES

HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens

DL Mann, E Read-Connole, LO Arthur, WG Robey, P Wernet, EM Schneider, WA Blattner and M Popovic
Section of Biochemical Epidemiology, National Cancer Institute, Bethesda, MD 20892.

The primary interaction of HIV-1 with the target cell involves the viral large envelope protein (gp120) and the cellular CD4 molecule. mAb reacting with portions of CD4 have been shown to block HIV-1 attachment and infection. In one of the early reports describing HIV-1 cell interaction, some mAb reacting with MHC class II Ag were also found to block infection. To investigate further a possible role for MHC class II in HIV-1 binding, a cultured T lymphocyte cell line (H-9) that expresses MHC class II molecules and PHA-stimulated PBL was exposed for various time periods to concentrated viral particles and individual HIV- 1 proteins. A decrease in the ability to detect the CD4a epitope and HLA-DR was observed after the cells were exposed to virus for 15, 30, and 60 min whereas HLA-DP and HLA-DQ Ag increased or remained unchanged. After 120 min of virus exposure, the CD4a epitope remained diminished whereas HLA-DR was detected at levels found on cells not exposed to virus. mAb detecting the CD4a epitope and HLA-DR, as well as alloantisera detecting the specific HLA-DR Ag on the target cell, blocked HIV-1 binding. When immunopurified gp120 was added to PHA- stimulated and unstimulated PBL, the CD4a epitope decreased in the same manner as was observed with whole virus preparations. In contrast to exposure to the intact virus, HLA-DR expression appeared to increase. Other viral proteins, p17, p24, and a portion of the small envelope protein, gp41, had no effect on the ability to detect cell surface Ag. Thus, although CD4 is the primary receptor for HIV-1 binding, HLA-DR appears to be involved in the binding site, probably by virtue of its close proximity to the CD4 molecule on the cell surface.

This article has been cited by other articles:

				C. Callebaut, E. Jacotot, B. Krust, G. Guichard, J. Blanco, A. Valenzuela, J. Svab, S. Muller, J.-P. Briand, and A. G. Hovanessian Pseudopeptide TASP Inhibitors of HIV Entry Bind Specifically to a 95-kDa Cell Surface Protein J. Biol. Chem., March 14, 1997; 272(11): 7159 - 7166. [Abstract] [Full Text] [PDF]

				L. Arthur, J. Bess Jr, R. Sowder 2nd, R. Benveniste, D. Mann, J. Chermann, and L. Henderson Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines Science, December 18, 1992; 258(5090): 1935 - 1938. [Abstract] [PDF]